Abstract: In exemplary examples, methods and systems for treating vascular disease by implanting a stent within the vasculature and using intravascular imaging to determine and ensure that the stent was property implanted and producing a desirable and effective results is disclosed herein. For example, a system may obtain optical shape sensing data and intravascular imaging data for a blood vessel. The system may process the optical shape sensing data and the intravascular imaging data to generate a three-dimensional model and image of the blood vessel immediately before and immediately after stent implantation into the blood vessel, and perform a precise comparison of the before and after images to ensure that the stent was properly implanted and will produce or is producing a desirable and effective result. The precise comparison may be based on a derived diameter associated with the location at which the stent is placed in the blood vessel based on the generated pre and post generated three-dimensional models.

Abstract: Drug delivery balloons have densely packed crystals of small particle size of the drug thereon. An amorphous drug coating is applied to a balloon surface and annealed to provide the crystals. The balloon surface is nucleated to induce formation of drug crystals in the annealing step to provide the crystals in high density with small size.

Abstract: A method of producing a drug coated balloon that comprises the steps of: subjecting a balloon catheter with a folded and wrapped balloon thereon to a pre-annealing step to induce a fold/wrap memory in the resulting pre-annealed balloon; unfolding the pre-annealed balloon sufficiently to expose the full circumferential surface of the balloon by application of an inflation pressure that retains said fold/wrap memory; applying a drug coating formulation to the unfolded balloon surface; releasing pressure to relax the balloon and induce creasing along fold memory; and evacuating the balloon slowly to induce refolding and rewrapping of the balloon. The method overcomes the need to use a folding apparatus to fold and wrap a drug coated balloon.

Abstract: A system for coating a medical device comprises a transfer web, a metering web. The webs are each advanced in a downstream direction toward a gap defined by the advancing webs. A coating solution applicator is configured to apply a coating solution at a staging area at a position upstream of the gap. A medical device retaining mechanism is positioned at a coating application area of the transfer web, at a position downstream from the gap.

Abstract: Drug delivery balloons have densely packed crystals of small particle size of the drug thereon. An amorphous drug coating is applied to a balloon surface and annealed to provide the crystals. The balloon surface is nucleated to induce formation of drug crystals in the annealing step to provide the crystals in high density with small size.

Abstract: This invention relates to silicone coating composition comprising a solventless silicone coating composition and a liquid silicone mist suppressant composition obtained by a method comprising reacting a large excess of at least one organohydrogensilicon compound containing at least three silicon-bonded hydrogen groups with at least one compound containing at least two alkenyl groups in the presence of a platinum group metal-containing catalyst.

Abstract: This invention relates to silicone coating composition comprising a solventless silicone coating composition and a liquid silicone mist suppressant composition obtained by a method comprising reacting a large excess of at least one organohydrogensilicon compound containing at least three silicon-bonded hydrogen groups with at least one compound containing at least two alkenyl groups in the presence of a platinum group metal-containing catalyst.

Abstract: This invention relates to silicone coating composition comprising a solventless silicone coating composition and a liquid silicone mist suppressant composition obtained by a method comprising reacting a large excess of at least one organohydrogensilicon compound containing at least three silicon-bonded hydrogen groups with at least one compound containing at least two alkenyl groups in the presence of a platinum group metal-containing catalyst.